Gene therapy for vascular disease

Current Opinion in Cardiology

Volumn 13, Issue 5, 1998, Pages 369-374

  Svensson, Eric C ^a   Schwartz, Lewis B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANGIOPLASTY; BYPASS SURGERY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CLONING VECTOR; DEVELOPED COUNTRY; GENE TARGETING; GENE THERAPY; HUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RESTENOSIS; REVIEW; VASCULAR DISEASE; VEIN GRAFT;

EID: 0031767532     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199809000-00009     Document Type: Review

References (88)

1. Avery OT, MacLeod CM, McCarty M: Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J ExpMed 1944, 79:137-158.
2. Jackson DA, Symons R, Berg P: Biochemical method for inserting new genetic information into DNA of simian virus 40: circular SV40 DNA molecules containing Lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci 1972, 69:2904-2909.
3. Chien KR, Knowlton KU: Cardiovascular molecular biology: introduction to the series. Circulation 1989, 80:219-233.
4. Wolff JA, Lederberg J: An early history of gene therapy. Hum Gene Ther 1994, 5:469-480.
5. Friedmann T: Overcoming the obstacles to gene therapy. Sci Am 1997, 276:96-101.
6. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994, 265:781-784.
7. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T: Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 1993, 88:2838-2848.
8. Chen S, Wilson JM, Muller DWM: Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 1994, 89:1922-1928.
9. Plautz G, Nabel EG, Nabel GJ: Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation 1991, 83:578-583.
10. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989, 244:1342-1344.
11. Lemarchand P, Jones M, Yamada I, Crystal RG: In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993, 72:1132-1138.
12. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA: In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993, 73:797-807.
13. Riessen R, Rahimizadeh H, Blessing E, Takeshita S, Barry JJ, Isner JM: Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther 1993, 4:749-758.
14. Steg PG, Feldman LJ, Scoazec J, Tahlil O, Barry JJ, Boulechfar S, et al.: Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 1994, 90:1648-1656.
15. Willard JE, Landau C, Glamann B, Burns D, Jessen ME, Pirwitz MJ, et al.: Genetic modification of the vessel wall: comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation 1994, 89:2190-2197.
16. Lim CS, Chapman GD, Gammon RS, Muhlestein JB, Bauman RP, Stack RS, Swain JL: Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog. Circulation 1991, 83:2007-2011.
17. Nabel EG, Plautz G, Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990, 249:1285-1288.
18. Leclerc G, Gal D, Takeshita S, Nikol S, Weir L, Isner JM: Percutaneous arterial gene transfer in a rabbit model. J Clin Invest 1992, 90:936-944.
19. French BA, Mazur W, Ali NM, Geske RS, Finnigan JP, Rodgers GP, et al.: Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of restenosis. Circulation 1994, 90:2402-2413.
20. Kim S, Lin H, Barr E, Chu L, Leiden JM, Parmacek MS: Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest 1997, 100:1006-1014. A replication-defective adenovirus vector was constructed that encodes the lacZ gene under transcriptional control of the smooth muscle cell-specific SM22α promotor (AdSM22-lacZ). After intra-arterial or intravenous transfection, lacZ was expressed only in smooth muscle cells. The ability to restrict transgene expression to certain cell types may help to limit toxicity of gene therapy.
21. Tripathy SK, Black HB, Goldwasser E, Leiden JM: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996, 2:545-550.
22. Muzyczka N: Use of adeno-associated virus as a general transduction vector for mammlian cells. Curr Top Microbiol Immunol 1992, 158:97-129.
23. Rolling F, Nong Z, Pisvin S, Collen D: Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther 1997, 4:757-761. High-level gene expression using adeno-associated virus carrying CMVlacZ was observed 30 days after infection. This is significantly longer than most studies using adenoviral vectors and may enable prolonged transgene expression.
24. Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL: Adeno-associated virus vectors for vascular gene delivery. Circ Res 1997, 80:497-505.
25. Kotin RM: Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994, 5:793-801.
26. Xiao X, Li J, Samulski RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996, 70:8098-8108.
27. Califf RM, Fortin DF, Fried DJ, Harlan WR III, Ohman EM, Bengston JR, et al.: Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol 1991, 17:2B-13B.
28. Gray BH, Sullivan TM, Young JR, Olin J: High incidence of restenosis/reocclusion of intravascular stents in the percutaneous treatment for long segment superficial femoral artery atherosclerotic disease. Soc Vasc Surg 1996, 50:66.
29. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK: A cascade model for restenosis: a special case of atherosclerosis progression. Circulation 1992, 86(suppl III):III-47-III-52.
30. Liu MW, Roubin GS, King SB III: Restenosis after coronary angioplasty: potential biologic determinants and role of intimai hyperplasia. Circulation 1989, 79:1374-1387.
31. Schwartz SM, deBlois D, O'Brien ERM: The intima: soil for atherosclerosis and restenosis. Circ Res 1995, 77:445-465.
32. Bennett MR, Schwartz SM: Antisense therapy for angioplasty restenosis: some critical considerations. Circulation 1995, 92:1981-1993.
33. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong SC, et al: Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996, 94:35-43.
34. Schwartz RS, Holmes DR Jr, Topol EJ: The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992, 20:1284-1293.
35. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T: In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci 1994, 91:10732-10736.
36. Chang MW, Ohno T, Gorson D, Lu MM, Nabel GJ, Nabel EG, Leiden JM: Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Mol Med 1995, 1:172-181.
37. Steg PG, Tahlil O, Aubailly N, Caillaud J-M, Dedieu J-F, Berthelot K, et al: Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 1997, 96:408-411.
38. Harrell RL, Rajanayagam S, Doanes AM, Guzman RJ, Hirschowitz EA, Crystal RG, et al: Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circlation 1997, 96:621-627.
39. Sata M, Perlman HR, Muruve DA, Ikebe M, Libermann TA, Oettgen P, Walsh K: Adenovirus-mediated fas ligand gene transfer inhibits neointima formation and confers immune privilege status to the vessel wall [abstract]. Circulation 1997, 96(suppl I):I-669.
40. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD: Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997, 96:3180-3191.
41. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al.: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci 1993, 90:8474-8478.
42. Pitsch RJ, Goodman GR, Minion DJ, Madura JA III, Fox PL, Graham LM: Inhibition of smooth muscle cell proliferation and migration in vitro by antisense oligonucleotide to c-myb. J Vasc Surg 1996, 23:783-791.
43. Shi Y, Fard A, Galeo A, Hutchingson HG, Vermani P, Didge GR, et al.: Transcatheter delivery of c-myc antisense oligers reduces neointimal formation in a procine model of coronary artery balloon injury. Circulation 1994, 90:944-951.
44. Indolfi C, Avvedimento EV, Rapacciuolo A, Lorenzo ED, Esposito G, Stabile E, et al.: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1995, 1:541-545.
45. Ludwig S, Rapp UR: Cascading towards vascular disorder gene therapy. Nat Med 1995, 1:513-515.
46. Shyy JY, Jin G, Li Y-S, Chien S: The use of rasN17 in gene therapy to prevent artery restenosis (abstract). Circulation 1997, 96(suppl I):I-669.
47. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995, 276:518-522.
48. Smith RC, Wills KN, Antelman D, Perlman H, Truong LN, Krasmski K, Walsh K: Adenoviral constructs encoding phosphorylation-component fulllength and truncated forms of the human retinoblastoma protein inhibit myoctye proliferation and neointima formation. Circulation 1997, 96:1899-1905. Adenoviral constructs encoding either amino-terminal-truncated (Rb56) or full-length retinoblastoma (Rb 110) were used to infect balloon-injured rat carotid arteries. Transfer was highly efficient as demonstrated by immunoblot analysis. After 14 days, neointima formation was reduced by 40% using either Rb form. These data corroborate an earlier study by Chang et al. [47] and confirm the usefulness of Rb as an inhibitor of smooth muscle cell replication in animal model [5].
49. Chang MW, Barr E, Lu MM, Barton K, Leiden JM: Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995, 95:2260-2268.
50. Ueno H, Haruno A, Morisaki N, Furuya M, Kangawa K, Takeshita A, Saito Y: Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 1997, 96:2272-2279. Smooth muscle cells were induced to secrete large amounts of C-type natriuretic peptide (CNP), a stimulator of membrane-bound guanylate cyclase, by transfection with an adenoviral vector (AdCACNP). Local infection of balloon-injured rat carotid arteries in vivo resulted in an impressive 90% reduction in neointima formation.
51. Chemla E, Castier Y, Julia P, Pirotski E, Carpentier A, Fabiani JN: Inhibition of intimai hyperplasia by an antisense oligonucleotide of farnesyl transferase delivered endoluminally during iliac angioplasty in a rabbit model. Ann Vasc Surg 1997, 11:581-587.
52. Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden MA: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. 1997, 25:320-325.
53. 10 PFU/mL into rabbit femoral arteries did not result in significant decreases in the proliferation index (BrdU labeling) but led to 50% reduction in I/M ratio after 14 days. These data and those presented in a related study by Hanna et al. [52] illustrate the importance of bFGF in smooth muscle cell proliferation and the potential therapeutic benefit of the antisense approach.
54. Zhu NL, Wu L, Liu PX, Gordon EM, Anderson WF, Starnes VA, Hall FL: Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 1997, 96:628-635.
55. DeWeese JA, Leather R, Porter J: Practice guidelines: lower extremity revascularization. J Vasc Surg 1993, 18:280-294.
56. Myler RK, Stertzer SH: Coronary and peripheral angioplasty: historical perspective. In Textbook of Interventional Cardiology, vol 2. Edited by Topol EJ. Philadelphia: WB Saunders; 1994:171-185.
57. Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lespèrance J: Long-term fate of bypass grafts: The Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation 1985, 72(suppl V):V-71-V-78.
58. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC: Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985, 89:248-258.
59. Donaldson MC, Whittemore AD, Mannick JA: Further experience with an all-autogenous tissue policy for infrainguinal reconstruction. J Vasc Surg 1993, 18:41-48.
60. Bergamini TM, George SM Jr, Massey HT, Henke PK, Klamer TW, Lambert GE, et al.: Intensive surveillance of femoropopliteal-tibial autogenous vein bypasses improves long-term graft patency and limb salvage. Ann Surg 1995, 221:507-516.
61. Donaldson MC, Mannick JA, Whittemore AD: Causes of primary graft failure after in situ saphenous vein bypass grafting. J Vasc Surg 1992, 15:113-120.
62. Erickson CA, Towne JB, Seabrook GR, Freischlag JA, Cambria RA: Ongoing vascular laboratory surveillance is essential to maximize long-term in situ saphenous vein bypass patency. J Vasc Surg 1996, 12:18-27.
63. Schwartz LB, Pence JC, Kerns BJ, Iglehart JD, McCann RL, Hagen P: Kinetics of experimental vein graft cell division and function. Surg Forum 1991, 27:363-365.
64. Golden MA: Modification of vein graft adaptation using adenoviral vectors. J Vasc Surg 1996, 24:161-163.
65. Moawad J, Schwartz LB, Gewertz BL, Chang MW, Leiden JM: Efficiency of adenoviral-mediated gene transfer in experimental vein grafts [abstract]. Midwest Society for Vascular Surgery, Chicago, IL, 1997.
66. Quax PHA, Lamfers MLM, Grimbergen J, Teeling J, van Nieuw Amerongen G, van Hinsbergh VMW: Effects of adenoviral infection on umbilical vein endothelial and smooth muscle cells [abstract]. J Vasc Res 1996, 33(suppl 1):320.
67. Channon KM, Fulton GJ, Gray JL, Annex BH, Shetty GA, Blazing MA, et al.: Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res 1997, 35:505-513. This is one of the few available studies on the efficiency of adenoviral gene transfer in vein grafts. Gene expression was efficiently achieved in endothelial cells but limited m the smooth muscle cell layer. Expression was maximal at 3 days but was fairly rapidly attenuated. This study and others [65] illustrate the difficulty in whole-vessel transfection when the endothelium is intact.
68. Kupfer JM, Ruan XM, Liu G, Matloff J, Forrester J, Chaux A: High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Hum Gene Ther 1994, 5:1437-1443.
69. Mann MJ, Gibbons GH, Hutchinson H, Diet FP, Dzau VJ: Effective antisense oligonucleotide transfection in human saphenous vein for the development of genetically engineered bypass grafts. Circulation 1995, 92(suppl I):I-642.
70. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, et al.: Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci 1995, 92:4502-4506.
71. Hong-zhi B, Yoshiki S, Tomoyuki Y, Wei-da Z, Ryuicki M, Junichi M, Matsuda H: Gene transfer of senescent cell-derived inhibitor 1 into vein graft inhibited neointimal hyperplasia in vivo associated with induction of smooth muscle cell redifferentiation. Circulation 1995, 92(suppl I):I-642.
72. Matsushita H, Morishita R, Kida I, Aoki M, Hayashi S, Tomita N, et al.: Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis. Hypertension 1998, 31(1 pt 2):493-498.
73. Fulton GJ, Davies MG, Lefkowitz RJ, Svendsen E, Koch WJ, Hagen P-O: Transfection with β ARKCT reduces intimai hyperplasia in experimental vein grafts. Surg Forum 1996, 47:341-345.
74. Quax PHA, Lamfers ML, Grimbergen JG, Verheijen JH, van Hinsberg V: Inhibition of neointima formation in cultured human saphenous vein segments by an adenovirus epressing an urokinase receptor binding plasmin inhibitor [abstract]. Circulation 1997, 96(suppl I):I-669.
75. Matsumoto T, Komori K, Yonemitsu Y, Morishita R, Sueishi K, Kaneda Y, Sugimachi K: Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimai hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 1998, 27:135-144. A well-characterized model of vein graft intimal hyperplasia under conditions of poor outflow was used to demonstrate the efficacy of HVJ-liposome-mediated ecNOS transfection in reducing neointima formation. Gene expression was confirmed in all layers of the vein graft wall after 4 days. After 4 weeks, vein graft neointimal thickness was reduced by 60%.
76. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al.: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci 1995, 92:5855-5859.
77. Mann MJ, Whittemore AD, Donaldson MC, Belkin MA, Orav J, Polak J, Dzau VJ: Preliminary clinical experience with genetic engineering of human vein grafts: evidence for target gene inhibition (abstract). Circulation 1997, 96(suppl I):I-4. Preliminary data are presented (in abstract form) from the first clinical trial of gene therapy for the prevention of vein graft neointimal hyperplasia. A small segment of the E2F ODN decoy-transfected graft was excised for cell culture assay. Greater than 60% inhibition proliferating cell nuclear antigen expression was demonstrated by reverse transcriptase polymerase chain reaction. No clinical data are presented.
78. DeFrang RD, Taylor LM Jr, Porter JM: Amputations. In Basic Data Underlying Clinical Decision Making in Vascular Surgery. Edited by Porter JM, Taylor LM Jr. St. Louis: Quality Medical Publishing; 1994:153-158.
79. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
80. Pepper MS: Positive and negative regulation of angiogenesis: from cell biology to the clinic. Vasc Med 1996, 1:259-266.
81. Isner JM: Therapeutic angiogenesis: A new frontier for vascular therapy. Vasc Med 1996, 1:79-87.
82. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, et al.: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimai hyperplasia in balloon-injured rat carotid artery. Circulation 1995, 91:2793-2801.
83. Muhlhauser J, Merrill MJ, Pili R, Maeda H, Bacic M, Bewig B, et al.: VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res 1995, 77:1077-1086.
84. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, et al.: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996, 94:1074-1082.
85. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, et al.: Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1996, 94:1074-1082.
86. 165 DNA was directly injected into lower extremity skeletal muscle in 10 limbs of nine patients with nonreconstructable peripheral vascular disease and either rest pain or tissue loss. There was a transient increase in serum VEGF levels, a significant increase in anklebrachial index, and limb salvage in 6 of 10 limbs.
87. Schumacher B, Pecher P, von Specht BU, Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 1998, 97:645-650. This is a report of the first clinical trial of direct angiogenic factor injection for stimulation of myocardial angiogenesis. Purified fibroblast growth factor (FGF)-1 (aFGF) 0.01 mg/kg body weight was injected in close proximity to the left anterior descending coronary artery distal anastomosis in 20 patients undergoing coronary revascularization. At follow-up angiography, new capillary formation was observed around the site of injection in all patients.
88. Folkman J: Angiogenic therapy of the human heart. Circulation 1998, 97:628-629.